CFDE Data Portal | Search CIBAR1P2

	Label	Description
	CIBAR1P2 Gene (Entity type)	ENSG00000293019 - CIBAR1 pseudogene 2
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE220283 STAT3 knockdown Hep-G2 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE176144 ZFC3H1 knockdown U2OS 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 9 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 9 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	SGK494 IDG kinase ARCHS4 coexpression Gene Set (Entity type)	A Gene Set from IDG
	TMC7 IDG ionchannel ARCHS4 coexpression Gene Set (Entity type)	A Gene Set from IDG
	KCNG4 IDG ionchannel ARCHS4 coexpression Gene Set (Entity type)	A Gene Set from IDG

CIBAR1P2

ENSG00000293019 - CIBAR1 pseudogene 2

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn

A Gene Set from LINCS

GSE220283 STAT3 knockdown Hep-G2 0 v 1 human dn

A Gene Set from LINCS

GSE100148 EZH2 inhibition 4 v 7 human dn

A Gene Set from LINCS

GSE176144 ZFC3H1 knockdown U2OS 0 v 1 human up

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 9 v 7 human dn

A Gene Set from LINCS

GSE100148 EZH2 inhibition 9 v 7 human dn

A Gene Set from LINCS

SGK494 IDG kinase ARCHS4 coexpression

A Gene Set from IDG

TMC7 IDG ionchannel ARCHS4 coexpression

A Gene Set from IDG

KCNG4 IDG ionchannel ARCHS4 coexpression

A Gene Set from IDG

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.